|
Hematech, Inc., a subsidiary of Kyowa Hakko Kirin, has developed the world's first large animal platform technology to produce fully human antibodies using the latest advances in gene engineering and transfer to produce new biopharmaceuticals that help fight disease.
The company, headquartered in Sioux Falls, South Dakota has developed a line of cattle that produce fully human antibodies. Hematech's patented process involves inserting human genes for antibody production into cattle and inactivating the native antibody genes. The genetically engineered cattle, known as Tc (Transchromosomal) Bovine™ are used to produce plasma derived polyclonal and recombinant human antibodies. These antibodies are developed for treatment of human diseases such as cancer, autoimmune disorders, inflammation, infectious diseases and others.
 |
Awarded 2008 South Dakota Business of the Year by the
South Dakota Chamber of Commerce and Industry. Read more |
|
|
 |
A Subsidiary of
Kyowa Hakko Kirin Company, Ltd.
4401 South Technology Drive
Sioux Falls, SD 57106 |
|
|
